Injectable nanodevices could provide effective treatment for drug-resistant glioblastoma

Glioblastoma, the most aggressive form of brain cancer, remains a formidable challenge for oncologists worldwide. Despite advances in surgical techniques, radiation, and chemotherapy, the disease carries a grim prognosis, with median survival ranging only from 12 to 15 months after diagnosis.

The tumor’s rapid growth and diffuse infiltration into surrounding brain tissue make complete resection nearly impossible, while its genetic heterogeneity fuels resistance to standard therapies. Current treatment protocols typically combine maximal safe resection, temozolomide chemotherapy, and concurrent radiotherapy, yet recurrence is almost inevitable. Researchers are exploring novel approaches—including immunotherapy, targeted agents, and precision medicine—to overcome these obstacles, but progress has been slow.

As the medical community continues to investigate new strategies, the outlook for glioblastoma patients remains bleak. Ongoing clinical trials and basic science studies are essential to improve survival and quality of life for those affected by this devastating disease.